Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

122.73
Delayed Data
As of Feb 24
 +1.03 / +0.85%
Today’s Change
102.97
Today|||52-Week Range
126.07
+6.53%
Year-to-Date
JNJ Regular Dividend: JNJ began trading ex-dividend on 02/24/17. A $0.80 dividend will be paid to shareholders of record as of 02/28/17.
US Market Indexes Gain for the Week
9:15am / GuruFocus News - Paid Partner Content
Johnson & Johnson (JNJ) Up 6% Since Earnings Report: Can It Continue?
Feb 24 / Zacks.com - Paid Partner Content
Calling a Market Top; The Price Is Wrong: Jim Cramer's Best Blog
Feb 24 / TheStreet.com - Paid Partner Content
Zacks Podcast Highlights: Can Companies Satisfy Their Investors by Satisfying Their C...
Feb 23 / Zacks.com - Paid Partner Content
Cramer: When Someone Calls a Market Top, What's Their Motivation?
Feb 24 / TheStreet.com - Paid Partner Content
Dow Jones Leads Market Gains on Thursday
Feb 23 / GuruFocus News - Paid Partner Content
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Feb 24 / MotleyFool.com - Paid Partner Content
3 All-or-Nothing Stocks We're Closely Watching
Feb 23 / MotleyFool.com - Paid Partner Content
Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order...
Feb 24 / Zacks.com - Paid Partner Content
Trump Meets With Top CEOs To Brainstorm "Jump-Starting" US Economy, Creating Jobs
Feb 23 / Investing Channel - Paid Partner Content

Today’s Trading

Previous close121.70
Today’s open121.50
Day’s range120.90 - 122.74
Volume10,834,986
Average volume (3 months)7,289,006
Market cap$333.9B
Dividend yield2.61%
Data as of 4:00pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)+8.21%
Earnings growth (this year)+4.73%
Earnings growth (next 5 years)+5.95%
Revenue growth (last year)+2.41%
P/E ratio21.5
Price/Sales4.47
Price/Book--

Competitors

 Today’s
change
Today’s
% change
PFEPfizer+0.20+0.59%
MRKMerck+0.31+0.47%
NVSNovartis-0.17-0.22%
SNYSanofi+0.19+0.45%
Data as of 4:02pm ET, 02/24/2017

Financials

Next reporting dateApril 18, 2017
EPS forecast (this quarter)$1.76
Annual revenue (last year)$71.9B
Annual profit (last year)$16.5B
Net profit margin23.01%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman &
Chief Executive Officer
Alex Gorsky
Chief Financial Officer &
Vice President
Dominic J. Caruso
Corporate headquarters
New Brunswick, New Jersey

Forecasts


Search for Jobs